Project: Developing Tools to assess Efficacy and Safety of the promising TEG treatment for solid tumors
| Acronym | TEST (Reference Number: 11497) |
| Duration | 01/01/2018 |
| Project Topic | GAD’s new technology TEG to create T-cell immunotherapies(TCI) targets many cancers through its unique MoA, targeting tumor cells by recognizing surface markers of metabolic dysregulation. GAD, HUB&CT can image and quantify efficacy of TEGs and their ability to discriminate between healthy vs malignant tissue using organoids&RamanSpectroscopy. TEST aims to create PoC for TEG002 in Triple Negative Breast Cancer(TNBC) in organoids and mice (UoF) and to deliver a screening platform for novel TCIs. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 7 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Gadeta B.V. | Coordinator | Netherlands |
| 2 | CellTool | Partner | Germany |
| 3 | Hubrecht Organoid Technology | Partner | Netherlands |
| 4 | Albert-Ludwigs-Universität Freiburg | Partner | Germany |